Visionary Holdings Enters Strategic Cooperation with Chushanji
Visionary Holdings entered into a strategic cooperation agreement with Zhejiang Chushanji Digital Technology Co. According to information provided by Chushanji, the company currently operates an extensive offline commercial network spanning 5 provinces and 105 district- and county-level markets in China, covering nearly 10,000 stores. Pursuant to the agreement, Chushanji is expected to assist Visionary in the marketing, channel development, distribution, and sales support of the Company's V-series anti-aging products in China. By leveraging Chushanji's existing offline business network and operational resources, the cooperation is intended to facilitate product promotion, channel penetration, and potential customer conversion across selected medical aesthetics and wellness service locations. Chushanji has developed an offline service network through its ongoing business activities, which may provide Visionary with access to a broad base of service locations and consumer touchpoints. Through this cooperation, the Company expects to explore scalable approaches for expanding market awareness and supporting the commercialization of its V-series anti-aging products in the Chinese market. Based on preliminary internal estimates, the Company believes that, if the collaboration progresses as expected and market adoption is achieved, annual revenue contribution from related products could potentially reach a range of approximately $10M to $15M over time.
Trade with 70% Backtested Accuracy
Analyst Views on GV
About GV
About the author


- Strategic Investment Agreement: Visionary Holdings has signed an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Management Co., Ltd., planning a $20 million investment for its anti-aging project in Qingdao, aimed at establishing a project company to enhance the company's influence in the Chinese market.
- Project Company Establishment: Under the agreement, the parties will jointly establish a project company focused on research and translational development in cell therapy and biologics, expected to drive the introduction of internationally aligned products and services, thereby expanding business in the Shandong market.
- Phased Investment Structure: The investment will be structured in two phases, with the initial $20 million disbursed through three milestone payments, ensuring the project company operates smoothly and achieves profitability, targeting profitability for the first anti-aging center within one year post-investment completion.
- Regional Support Measures: The agreement includes a range of implementation support measures, such as coordinating local resources in Qingdao, providing preferential office and R&D space, aimed at accelerating project implementation and enhancing the company's competitiveness in the life sciences sector.
- Strategic Cooperation Agreement: Visionary Holdings Inc. has signed a strategic cooperation agreement with Zhejiang Chushanji Digital Technology Co., Ltd. to leverage Chushanji's extensive offline commercial network in China, which spans nearly 10,000 stores, significantly enhancing the market penetration of its V-series anti-aging products.
- Market Potential Assessment: Based on preliminary internal estimates, if the collaboration progresses as expected, the annual revenue contribution from related products could potentially reach between $10 million and $15 million, providing crucial support for the company's commercialization strategy in the Chinese market.
- Channel Development Advantage: Chushanji's extensive network across five provinces and 105 district and county markets will offer Visionary a broad base of service locations and consumer touchpoints, thereby enhancing its market access capabilities in the medical aesthetics and wellness sectors, driving product sales and brand awareness.
- Execution Risk Advisory: While the initial phase of the cooperation shows promising market potential, the company emphasizes that actual results will be influenced by market demand, execution efficiency, and regulatory factors, making future financial impacts uncertain and warranting cautious consideration.
- Exclusive Distribution Agreement: Visionary Holdings' wholly owned subsidiary has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, significantly enhancing market penetration and revenue visibility for its anti-aging product.
- Core Business Focus: The company's board approved the divestiture of 100% equity interests in non-core operations, completing the exit from legacy businesses to concentrate resources on high-margin medical aesthetics and biotechnology innovation, thereby improving capital efficiency and financial flexibility.
- Increased Market Acceptance: The commercialization milestone for Premier Regenerative Complex – President Super Injection signifies the company's formal transition into the high-end medical aesthetics market, reflecting growing market acceptance and bolstering confidence in future revenue growth.
- Management Outlook: The CEO stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-driven growth phase focused on anti-aging injectables and regenerative medical aesthetics, which is expected to drive sustainable expansion and revenue growth.

- Distribution Agreement: Visionary Holdings has signed a $12 million exclusive distribution agreement with Huajin in China.
- Market Expansion: This partnership aims to enhance Visionary Holdings' market presence and distribution capabilities in the Chinese market.
- International Market Expansion: Visionary Holdings plans to expand its presence in the North American and European medical aesthetics markets from 2026 to 2027 through product commercialization and international distribution partnerships, which is expected to significantly enhance the company's market share in global healthcare services.
- Anti-Aging Product Commercialization: The company anticipates that its RAMU anti-aging product line will become a key revenue growth driver over the next two years, with projected annual sales reaching approximately $30 million, reflecting strong market demand and high-margin potential in the medical aesthetics sector.
- Integrated Healthcare Services Platform Development: Visionary intends to develop an integrated healthcare services platform that combines medical aesthetics products with advanced biotechnology applications, aiming to enhance customer experience and strengthen market competitiveness, thereby driving long-term growth in the healthcare sector.
- Strategic Transition Progress: The CEO stated that Visionary is actively advancing its strategic transition towards healthcare services and aesthetics, with 2026 to 2027 expected to be a crucial stage for product commercialization and international expansion, potentially leading to significant growth opportunities for the company.
- Exclusive Distribution Agreement: Visionary Health Technology Group has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, which is expected to significantly enhance the company's revenue visibility in the high-end medical aesthetics market.
- Core Business Focus: The company's board approved the transfer of 100% equity interests in Visionary Education Services, marking Visionary Holdings' formal exit from non-core education operations, allowing a concentration on anti-aging injectables and regenerative medical aesthetics to improve capital efficiency.
- Increased Market Acceptance: The acceleration of the commercialization process for Premier Regenerative Complex – President Super Injection reflects growing market acceptance, which is anticipated to drive the company's growth in the global medical aesthetics sector.
- Management Strategy: CEO Xiyong Hou stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-centered growth phase focused on high-margin, high-growth medical aesthetics and biotechnology innovation, thereby enhancing financial flexibility.





